HIV Landscape Includes 1,000 Clinical Trials

Novotech recently released the latest global clinical trial landscape report on HIV, a condition now affecting more than 39 million people.

According to the HIV Global Clinical Trial Landscape report published on December 18, 2023, the biopharma industry has initiated over 1,000 HIV clinical trials worldwide since 2018.

The distribution of the trials is as follows: Asia-Pacific accounts for 29% of trials, Europe at 28%, and North America at 26%, while the Rest of the World contributes a moderate share of 17%.

The report delves into the multifaceted landscape of HIV, focusing on its impact, treatment, and global initiatives.

It begins by elucidating HIV's progression, from its attack on the immune system to the potential development of AIDS. In the United States, there were 1.2 million HIV cases, leading to 19,986 deaths in 2022.

At the report's core lies the worldwide strategy articulated by organizations such as WHO, the Global Fund, and UNAIDS to eradicate the HIV epidemic by 2030.

Moreover, the report explores cutting-edge research, including long-acting injectables, HIV vaccines, and gene editing, underscoring the potential to find an HIV cure.

As of December 31, 2023, there are no approved HIV vaccines available, but several vaccine candidates are conducting studies.

Novotech's research analyst team provides these expert reports every month, free of charge.